Cargando…

Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies

Background: The modern concept of oligometastatic (OM) state has been initially developed to describe patients with a low burden of disease and with a potential for cure with local ablative treatments. We systematically assessed the risk of death and relapse of oligometastatic (OM) cancers compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Ghidini, Antonio, Ghidini, Michele, Bukovec, Roberta, Trevisan, Francesca, Turati, Luca, Indini, Alice, Seghezzi, Silvia, Lonati, Veronica, Moleri, Giovanna, Tomasello, Gianluca, Zaniboni, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106994/
https://www.ncbi.nlm.nih.gov/pubmed/35602670
http://dx.doi.org/10.12688/f1000research.52546.4
_version_ 1784708393485729792
author Petrelli, Fausto
Ghidini, Antonio
Ghidini, Michele
Bukovec, Roberta
Trevisan, Francesca
Turati, Luca
Indini, Alice
Seghezzi, Silvia
Lonati, Veronica
Moleri, Giovanna
Tomasello, Gianluca
Zaniboni, Alberto
author_facet Petrelli, Fausto
Ghidini, Antonio
Ghidini, Michele
Bukovec, Roberta
Trevisan, Francesca
Turati, Luca
Indini, Alice
Seghezzi, Silvia
Lonati, Veronica
Moleri, Giovanna
Tomasello, Gianluca
Zaniboni, Alberto
author_sort Petrelli, Fausto
collection PubMed
description Background: The modern concept of oligometastatic (OM) state has been initially developed to describe patients with a low burden of disease and with a potential for cure with local ablative treatments. We systematically assessed the risk of death and relapse of oligometastatic (OM) cancers compared to cancers with more diffuse metastatic spread, through a meta-analysis of published data.  Methods: PubMed, the Cochrane Library, and EMBASE were searched for studies reporting prognosis of patients with OM solid tumors. Risk of death and relapse were extracted and pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI).  The primary outcome of the study refers to overall mortality in OM vs. polymetastatic (PM) patients.  Results. Mortality and relapse associated with OM state in patients with cancer were evaluated among 104,234 participants (n=173 studies). Progression-free survival was better in patients with OM disease (hazard ratio [HR] = 0.62, 95% CI 0.57–0.68; P <.001; n=69 studies). Also, OM cancers were associated with a better overall survival (OS) (HR = 0.65, 95% CI 0.62-0.68; P<.01; n=161 studies). In colorectal (CRC), breast, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) the reduction in the risk of death for OM patients were 35, 38, 30 and 42%, respectively. Biliary tract and cervical cancer do not significantly better in OM stage likely for paucity of data. Conclusions. Patients with OM cancers have a significantly better prognosis than those with more widespread stage IV tumors. In OM cancer patients a personalized approach should be pursued.
format Online
Article
Text
id pubmed-9106994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-91069942022-05-20 Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies Petrelli, Fausto Ghidini, Antonio Ghidini, Michele Bukovec, Roberta Trevisan, Francesca Turati, Luca Indini, Alice Seghezzi, Silvia Lonati, Veronica Moleri, Giovanna Tomasello, Gianluca Zaniboni, Alberto F1000Res Systematic Review Background: The modern concept of oligometastatic (OM) state has been initially developed to describe patients with a low burden of disease and with a potential for cure with local ablative treatments. We systematically assessed the risk of death and relapse of oligometastatic (OM) cancers compared to cancers with more diffuse metastatic spread, through a meta-analysis of published data.  Methods: PubMed, the Cochrane Library, and EMBASE were searched for studies reporting prognosis of patients with OM solid tumors. Risk of death and relapse were extracted and pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI).  The primary outcome of the study refers to overall mortality in OM vs. polymetastatic (PM) patients.  Results. Mortality and relapse associated with OM state in patients with cancer were evaluated among 104,234 participants (n=173 studies). Progression-free survival was better in patients with OM disease (hazard ratio [HR] = 0.62, 95% CI 0.57–0.68; P <.001; n=69 studies). Also, OM cancers were associated with a better overall survival (OS) (HR = 0.65, 95% CI 0.62-0.68; P<.01; n=161 studies). In colorectal (CRC), breast, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) the reduction in the risk of death for OM patients were 35, 38, 30 and 42%, respectively. Biliary tract and cervical cancer do not significantly better in OM stage likely for paucity of data. Conclusions. Patients with OM cancers have a significantly better prognosis than those with more widespread stage IV tumors. In OM cancer patients a personalized approach should be pursued. F1000 Research Limited 2022-05-12 /pmc/articles/PMC9106994/ /pubmed/35602670 http://dx.doi.org/10.12688/f1000research.52546.4 Text en Copyright: © 2022 Petrelli F et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Systematic Review
Petrelli, Fausto
Ghidini, Antonio
Ghidini, Michele
Bukovec, Roberta
Trevisan, Francesca
Turati, Luca
Indini, Alice
Seghezzi, Silvia
Lonati, Veronica
Moleri, Giovanna
Tomasello, Gianluca
Zaniboni, Alberto
Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies
title Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies
title_full Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies
title_fullStr Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies
title_full_unstemmed Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies
title_short Better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies
title_sort better survival of patients with oligo- compared with polymetastatic cancers:  a systematic review and meta-analysis of 173 studies
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106994/
https://www.ncbi.nlm.nih.gov/pubmed/35602670
http://dx.doi.org/10.12688/f1000research.52546.4
work_keys_str_mv AT petrellifausto bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT ghidiniantonio bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT ghidinimichele bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT bukovecroberta bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT trevisanfrancesca bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT turatiluca bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT indinialice bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT seghezzisilvia bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT lonativeronica bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT molerigiovanna bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT tomasellogianluca bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies
AT zanibonialberto bettersurvivalofpatientswitholigocomparedwithpolymetastaticcancersasystematicreviewandmetaanalysisof173studies